Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00602719 · ClinicalTrials.gov registry record · NA

Bioequivalency Study of Zolpidem Tartrate Under Fed Conditions

A NA study of Insomnia, sponsored by Roxane Laboratories.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT00602719: Completed NA study of Insomnia, sponsored by Roxane Laboratories.

NCT00602719 is a NA study of Insomnia that has completed, run by Roxane Laboratories. The registered enrollment target is 30 participants, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00602719, a NA study of Insomnia, has completed, sponsored by Roxane Laboratories.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The objective of this study was the bioequivalence of a Roxane Laboratories' Zolpidem Tablets, 10 mg, to Ambien® Tablets, 10 mg (Sanofi-Synthelabo Inc.) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.

Conditions Studied

Interventions

  • DRUG Zolpidem

Study Locations (1)

North Dakota

  • PRACS Institute, Ltd. - Fargo

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2004-03
Est. Completion 2004-03
Phase NA
Roxane Laboratories

93 total trials

What the finished NCT00602719 record still lists

NCT00602719 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (82% lower).

The record links to 1 condition, with Insomnia appearing as the primary indexed condition, and to 1 intervention - of which Zolpidem is the first listed.

NCT00602719 reports a single indexed study location in North Dakota.

Frequently Asked Questions

What is clinical trial NCT00602719 about?

NCT00602719 is a clinical study titled "Bioequivalency Study of Zolpidem Tartrate Under Fed Conditions". The objective of this study was the bioequivalence of a Roxane Laboratories' Zolpidem Tablets, 10 mg, to Ambien® Tablets, 10 mg (Sanofi-Synthelabo Inc.) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.

What is the current status of trial NCT00602719?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2004-03. Estimated completion is 2004-03.

What conditions does trial NCT00602719 study?

This clinical trial studies the following conditions: Insomnia.

What interventions are being tested in trial NCT00602719?

The interventions under investigation include: Zolpidem (DRUG).

Who is sponsoring clinical trial NCT00602719?

This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00602719 being conducted?

This trial has 1 study location across North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Insomnia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00602719's enrollment target sits among peer trials

30 122nd of 151 higher than 25 of 151 other Insomnia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Insomnia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00602719, the US trial registry maintained by the National Library of Medicine. NCT00602719 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.